<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491764</url>
  </required_header>
  <id_info>
    <org_study_id>P05082</org_study_id>
    <nct_id>NCT00491764</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)</brief_title>
  <official_title>An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of oral
      administration of four dosing regimens of posaconazole relative to placebo and terbinafine,
      in the treatment of toenail onychomycosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Cure of Onychomycosis at Week 48.</measure>
    <time_frame>Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48</time_frame>
    <description>Complete cure is defined as negative mycology (negative culture and KOH [potassium hydroxide]) and 0% nail involvement (defined as absence of onycholysis and subungual hyperkeratosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effective Treatment of Onychomycosis at Week 48.</measure>
    <time_frame>Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48</time_frame>
    <description>Effective treatment is defined as negative mycology (negative culture and KOH) and either 0% nail involvement or &gt;5 mm growth of unaffected nail</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Success of Onychomycosis at Week 48</measure>
    <time_frame>Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48</time_frame>
    <description>Treatment success was defined as negative mycology (negative culture and negative KOH) and =&lt;10% nail involvement.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Posaconazole 100 mg QD for 24 weeks.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posaconazole 200 mg QD for 24 weeks.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posaconazole 400 mg QD for 24 weeks.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posaconazole 400 mg QD for 12 weeks.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Terbinafine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terbinafine 250 mg QD for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 56592</intervention_name>
    <description>Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.</description>
    <arm_group_label>Posaconazole 100 mg QD for 24 weeks.</arm_group_label>
    <other_name>Posaconazole</other_name>
    <other_name>Noxafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 56592</intervention_name>
    <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.</description>
    <arm_group_label>Posaconazole 200 mg QD for 24 weeks.</arm_group_label>
    <other_name>Posaconazole</other_name>
    <other_name>Noxafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 56592</intervention_name>
    <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.</description>
    <arm_group_label>Posaconazole 400 mg QD for 24 weeks.</arm_group_label>
    <other_name>Posaconazole</other_name>
    <other_name>Noxafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 56592</intervention_name>
    <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.</description>
    <arm_group_label>Posaconazole 400 mg QD for 12 weeks.</arm_group_label>
    <other_name>Posaconazole</other_name>
    <other_name>Noxafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine</intervention_name>
    <description>Terbinafine 250 mg QD for 12 weeks.</description>
    <arm_group_label>Terbinafine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must meet ALL the criteria listed below for entry:

               -  Subject must be between 18 and 75 years of age inclusive, of either sex, and of
                  any race;

               -  Subject must have distal subungual infection that affects approximately 25% to
                  75% of at least one great toenail, both clinically and mycologically diagnosed;

               -  Subject must have at least 2 mm of the proximal end of the target toenail free of
                  infection;

               -  Subject must have a target toenail that is assessed as capable of growing
                  approximately 1 mm/month, (eg, the subject needs to report cutting his or her
                  toenails at least once per month);

               -  Subject must have liver function tests within 1.5 x the upper limit of normal
                  (bilirubin and transaminases);

               -  Subject must have normal serum creatinine levels;

               -  Subject must be able to take study medication orally;

               -  Subject must have no history of current narcotic or alcohol addiction;

               -  Subject must be willing to give written informed consent and able to adhere to
                  dose, procedures, and visit schedules;

               -  Woman of childbearing potential who is currently sexually active must agree to
                  use a medically accepted method of contraception while receiving
                  protocol-specified medication and for 30 days after stopping the medication.
                  Methods include condoms (male or female) with or without a spermicidal agent,
                  diaphragm or cervical cap with spermicide, medically prescribed intrauterine
                  device, oral or systemic hormonal contraceptive (plus an additional reliable
                  barrier method), and surgical sterilization (eg, hysterectomy or tubal ligation).

        Woman of child-bearing potential who is not currently sexually active must agree to use a
        medically accepted method of contraception should she become sexually active while
        participating in the study.

          -  Woman of childbearing potential must have a negative serum pregnancy test within 72
             hours prior to start of study drug.

        Exclusion Criteria:

          -  The subject will be excluded from entry if ANY of the criteria listed below are met:

               -  Subject with one or more of the following conditions on the target toenail:

                    -  proximal subungual onychomycosis,

                    -  white superficial onychomycosis,

                    -  dermatophytoma or &quot;yellow spike/streak&quot;,

                    -  exclusively lateral disease,

                    -  inability to become normal in the opinion of the investigator.

               -  Subject with psoriasis, severe moccasin-type tinea pedis requiring treatment,
                  symptomatic interdigital tinea pedis, lichen planus, or other abnormalities that
                  could result in a clinically abnormal nail;

               -  Subject with peripheral vascular disease or peripheral circulatory impairment;

               -  Subject with history of uncontrolled diabetes mellitus;

               -  Subject with known chronic or active liver disease;

               -  Subject with any known immunodeficiency;

               -  Subject with a family history of long QT syndrome;

               -  Subject with an electrocardiogram with QTc interval prolongation greater than 450
                  msec for males and 470 msec for females;

               -  Subject with potassium or magnesium lower than the lower limit of normal;

               -  Subject with any clinically significant condition or situation, other than the
                  condition being studied that, in the opinion of the investigator, would interfere
                  with study evaluations or optimal participation in the study;

               -  Subject who has received systemic antifungal therapy within 3 months or topical
                  antifungal therapy applied to the foot or toenails within 1 month of study entry;

               -  Subject who has received radiation therapy, chemotherapy, and/or
                  immunosuppressive drugs within 6 months of Randomization, and/or oral
                  corticosteroids for &gt;1 month within the 6 months of Randomization (exception:
                  inhaled steroids);

               -  Subject using medications known to interact with azoles such as terfenadine,
                  pimozide, quinidine, halofantrine, astemizole, alfentanil, cisapride, HMG-Co A
                  (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors that are metabolized
                  by CYP3A4, and ebastine, within 7 days prior to Randomization; and pravastatin
                  within 14 days prior to Randomization;

               -  Subject using medications known to lower the serum concentration/efficacy of
                  azoles including rifampin, rifabutin, cimetidine, carbamazepine, phenytoin,
                  barbiturates, and isoniazid, 3 doses or more within 7 days prior to
                  Randomization;

               -  Subject with a known sensitivity to azoles, POS and/or its excipients,
                  terbinafine and/or its excipients;

               -  Subject who has been previously enrolled in this study or any other POS
                  investigational trial;

               -  Subject known to have received treatment with investigational drugs within 30
                  days prior to enrollment into this study;

               -  Woman who is breastfeeding, pregnant, or intends to become pregnant;

               -  Subject who is part of the staff personnel directly involved with this study;

               -  Subject who is a family member of the investigational study staff.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>December 23, 2009</results_first_submitted>
  <results_first_submitted_qc>December 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2010</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 690 subjects were enrolled in the study and screened for eligibility. A total of 472 were screen-failures, leaving 218 subjects randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Posaconazole 100 mg QD for 24 Weeks</title>
          <description>Posaconazole oral suspension (40 mg/mL) 100 mg daily (QD) for 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Posaconazole 200 mg QD for 24 Weeks.</title>
          <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Posaconazole 400 mg QD for 24 Weeks.</title>
          <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Posaconazole 400 mg QD for 12 Weeks.</title>
          <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Terbinafine 250 mg QD for 12 Weeks.</title>
          <description>Terbinafine 250 mg QD for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Placebo for 24 Weeks</title>
          <description>Placebo for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non Compliance with the Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not Meet Protocol Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Posaconazole 100 mg QD for 24 Weeks</title>
          <description>Posaconazole oral suspension (40 mg/mL) 100 mg daily (QD) for 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Posaconazole 200 mg QD for 24 Weeks.</title>
          <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Posaconazole 400 mg QD for 24 Weeks.</title>
          <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Posaconazole 400 mg QD for 12 Weeks.</title>
          <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Terbinafine 250 mg QD for 12 Weeks.</title>
          <description>Terbinafine 250 mg QD for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Placebo for 24 Weeks</title>
          <description>Placebo for 24 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="36"/>
            <count group_id="B5" value="36"/>
            <count group_id="B6" value="36"/>
            <count group_id="B7" value="218"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="13.0"/>
                    <measurement group_id="B2" value="53.6" spread="10.8"/>
                    <measurement group_id="B3" value="49.9" spread="13.2"/>
                    <measurement group_id="B4" value="53.5" spread="11.8"/>
                    <measurement group_id="B5" value="50.1" spread="12.2"/>
                    <measurement group_id="B6" value="48.4" spread="14.8"/>
                    <measurement group_id="B7" value="50.8" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Cure of Onychomycosis at Week 48.</title>
        <description>Complete cure is defined as negative mycology (negative culture and KOH [potassium hydroxide]) and 0% nail involvement (defined as absence of onycholysis and subungual hyperkeratosis).</description>
        <time_frame>Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48</time_frame>
        <population>This analysis was based on all randomized subjects who had a baseline assessment and at least one post-baseline assessment available, and who had been exposed to at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole 100 mg QD for 24 Weeks</title>
            <description>Posaconazole oral suspension (40 mg/mL) 100 mg daily (QD) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Posaconazole 200 mg QD for 24 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Posaconazole 400 mg QD for 24 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Posaconazole 400 mg QD for 12 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Terbinafine 250 mg QD for 12 Weeks.</title>
            <description>Terbinafine 250 mg QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo for 24 Weeks</title>
            <description>Placebo for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Cure of Onychomycosis at Week 48.</title>
          <description>Complete cure is defined as negative mycology (negative culture and KOH [potassium hydroxide]) and 0% nail involvement (defined as absence of onycholysis and subungual hyperkeratosis).</description>
          <population>This analysis was based on all randomized subjects who had a baseline assessment and at least one post-baseline assessment available, and who had been exposed to at least one dose of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>22.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.9</ci_lower_limit>
            <ci_upper_limit>36.8</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>54.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>38.0</ci_lower_limit>
            <ci_upper_limit>70.1</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>45.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>28.5</ci_lower_limit>
            <ci_upper_limit>62.4</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>20.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>6.7</ci_lower_limit>
            <ci_upper_limit>33.3</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>37.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>21.1</ci_lower_limit>
            <ci_upper_limit>53.2</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effective Treatment of Onychomycosis at Week 48.</title>
        <description>Effective treatment is defined as negative mycology (negative culture and KOH) and either 0% nail involvement or &gt;5 mm growth of unaffected nail</description>
        <time_frame>Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48</time_frame>
        <population>This analysis was based on all randomized subjects who had a baseline assessment and at least one post-baseline assessment available, and who had been exposed to at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole 100 mg QD for 24 Weeks</title>
            <description>Posaconazole oral suspension (40 mg/mL) 100 mg daily (QD) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Posaconazole 200 mg QD for 24 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Posaconazole 400 mg QD for 24 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Posaconazole 400 mg QD for 12 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Terbinafine 250 mg QD for 12 Weeks.</title>
            <description>Terbinafine 250 mg QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo for 24 Weeks</title>
            <description>Placebo for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Treatment of Onychomycosis at Week 48.</title>
          <description>Effective treatment is defined as negative mycology (negative culture and KOH) and either 0% nail involvement or &gt;5 mm growth of unaffected nail</description>
          <population>This analysis was based on all randomized subjects who had a baseline assessment and at least one post-baseline assessment available, and who had been exposed to at least one dose of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>25.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.2</ci_lower_limit>
            <ci_upper_limit>40.2</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>64.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>49.5</ci_lower_limit>
            <ci_upper_limit>80.2</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>48.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>31.4</ci_lower_limit>
            <ci_upper_limit>65.5</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.0</ci_lower_limit>
            <ci_upper_limit>46.8</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>54.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>37.8</ci_lower_limit>
            <ci_upper_limit>70.8</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Success of Onychomycosis at Week 48</title>
        <description>Treatment success was defined as negative mycology (negative culture and negative KOH) and =&lt;10% nail involvement.</description>
        <time_frame>Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48</time_frame>
        <population>This analysis was based on all randomized subjects who had a baseline assessment and at least one post-baseline assessment available, and who had been exposed to at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole 100 mg QD for 24 Weeks</title>
            <description>Posaconazole oral suspension (40 mg/mL) 100 mg daily (QD) for 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Posaconazole 200 mg QD for 24 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Posaconazole 400 mg QD for 24 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Posaconazole 400 mg QD for 12 Weeks.</title>
            <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Terbinafine 250 mg QD for 12 Weeks.</title>
            <description>Terbinafine 250 mg QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo for 24 Weeks</title>
            <description>Placebo for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Success of Onychomycosis at Week 48</title>
          <description>Treatment success was defined as negative mycology (negative culture and negative KOH) and =&lt;10% nail involvement.</description>
          <population>This analysis was based on all randomized subjects who had a baseline assessment and at least one post-baseline assessment available, and who had been exposed to at least one dose of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.0</ci_lower_limit>
            <ci_upper_limit>46.8</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>64.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>49.5</ci_lower_limit>
            <ci_upper_limit>80.2</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>66.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>50.6</ci_lower_limit>
            <ci_upper_limit>82.8</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.0</ci_lower_limit>
            <ci_upper_limit>46.8</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>57.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40.7</ci_lower_limit>
            <ci_upper_limit>73.5</ci_upper_limit>
            <estimate_desc>Difference is in the proportion for Yes responders. Confidence Interval is around the difference in proportions.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number of participants at risk included the 216 subjects who received treatment. Of the 218 subjects randomized, 1 subject in the posaconazole 100 mg and 1 subject in the placebo group were not treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Posaconazole 100 mg QD for 24 Weeks</title>
          <description>Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Posaconazole 200 mg QD for 24 Weeks</title>
          <description>Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Posaconazole 400 mg QD for 24 Weeks</title>
          <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks</description>
        </group>
        <group group_id="E4">
          <title>Posaconazole 400 mg QD for 12 Weeks</title>
          <description>Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>Terbinafine 250 mg QD for 12 Weeks</title>
          <description>Terbinafine 250 mg QD for 12 weeks</description>
        </group>
        <group group_id="E6">
          <title>Placebo for 24 Weeks</title>
          <description>Placebo for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HYPERCHLORHYDRIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AGEUSIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="13" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INGROWING NAIL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>ONYCHALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI must provide to sponsor 45 days prior to submission for publication/presentation, review copies of content to be presented that contains any results of the study. The sponsor has the right to review/comment with regard to proprietary information, accuracy, and fair balance. If disagreements arise concerning appropriateness of content to be presented, investigator must meet with sponsor prior to submission for publication to make good faith efforts to discuss/resolve any issues/disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

